NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of Lantheus Holdings, Inc. (NASDAQ: LNTH)?Did you purchase your shares between February 26, 2025 and August 5, 2025, inclusive?D ...

NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Charter Communications, Inc. (NASDAQ: CHTR) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Charter, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/charter-communications-inc-class-action-lawsuit. Investors have until October 14, 2025, to ask ...

NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in RxSight, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/rxsight-inc-class-action-lawsuit. Investors have until September 22, 2025, to ask the Court to ...

公司业务与商业模式 - RxSight是一家商业阶段医疗技术公司 专注于白内障治疗领域 其核心产品为RxSight Light Adjustable Lens系统 包括可调节人工晶体（LAL）和光传输设备（LDD）[3] - 公司采用"剃须刀/刀片"商业模式 通过扩大高单价LDD设备的装机量来驱动重复性、高利润的LAL手术量增长[3] 诉讼指控内容 - 指控公司在2024年5月7日至2025年7月8日期间虚假宣称装机基地使用率"全面提升" 且新客户群体采用速度与早期客户相当或更快[4] - 指控公司实地团队组织架构存在缺陷且表现不佳 新客户群体需要更多支持且采用速度较慢 装机基地整体使用率实际上处于下降趋势[4] - 指控公司增量LDD设备投放未能转化为预期LAL手术量 严重破坏了公司的增长模式[4] 股价重大变动事件 - 2025年4月2日公司披露季度LAL销售额环比下降 并将全年收入指引下调约2400万美元 导致股价单日下跌约38%[5] - 2025年7月8日公司进一步披露LDD销售额环比暴跌45% LAL销售额连续第二个季度下降 承认新客户需要更多支持且采用速度较慢 股价再次下跌约38%[6] 法律程序信息 - 集体诉讼案件编号为Gémesi v RxSight, Inc, No 25-cv-02093 此前另有案件Makaveev v RxSight, Inc, No 25-cv-01596[1] - 主导原告动议必须在2025年9月22日前向法院提交 投资者可通过指定链接或电话800/449-4900联系律师事务所[2][8]

Accessibility StatementSkip Navigation SAN DIEGO, Sept. 17, 2025 /PRNewswire/ --Â Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Dow Inc. (NYSE: DOW) securities between January 30, 2025 and July 23, 2025, both dates inclusive (the "Class Period"), have until Tuesday, October 28, 2025 to seek appointment as lead plaintiff of the Dow class action lawsuit. Captioned Sarti v. Dow Inc., No. 25-cv-12744 (E.D. Mich.), the Dow class action lawsuit charges Dow, The Dow Chemical Company, a ...

公司业务与产品 - Lantheus公司专注于开发、制造和商业化诊断和治疗产品 帮助全球临床医生诊断和治疗心脏病、癌症及其他疾病 [3] - 公司核心放射性药物肿瘤产品为Pylarify 这是一种用于辅助诊断和治疗前列腺癌的PET显像剂 [3] 财务表现与业绩指引 - 2025年第一季度Pylarify销售额出现同比下降 原因被归咎于"暂时性竞争干扰" [5] - 公司因此下调全年业绩指引 将年度增长预期从"低个位数到中个位数增长"调整为"持平至低个位数增长" [5] - 2025年8月6日公告显示Pylarify销售额同比下降8.3% 公司进一步大幅削减2025财年增长预期 [6] 股价表现与市场反应 - 2025年5月7日第一季度业绩公布后 公司股价单日跌幅超过23% [5] - 2025年8月6日第二次下调增长预期后 公司股价再次出现近29%的大幅下跌 [6] 法律诉讼情况 - 集体诉讼指控期间为2025年2月26日至8月5日 原告申请截止日期为2025年11月10日 [1] - 诉讼指控公司高管违反1934年证券交易法 称其营造了关于收入前景和增长预期的虚假印象 [4] - 指控称公司未能准确理解Pylarify市场的定价和竞争动态 其关于销售增长潜力和价格正常化的乐观报告与实际情况存在差距 [4]

Accessibility StatementSkip Navigation PHILADELPHIA, Sept. 17, 2025 /PRNewswire/ -- Berger Montague PC, a nationally recognized securities litigation law firm, is investigating potential securities law violations involving RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST). A class action lawsuit was recently filed on behalf of investors who acquired RxSight securities between May 7, 2024 and July 8, 2025 (the "Class Period"). Caitlin AdorniBerger Montague(267) 764-4865[email protected] SOURCE Berg ...

MIAMI, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Shamis & Gentile, P.A. is investigating potential securities claims on behalf of investors of Coherent Corp. ("Coherent" or the "Company") (NYSE: COHR) resulting from allegations that Coherent may have issued materially misleading business information to the investing public. Investors who purchased Coherent securities are encouraged to contact the law firm more information at: Coherent Corp. Securities Investigation What Is This About? On August 13, 2025, Coherent ...

SAN DIEGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Snap Inc. (NYSE: SNAP) securities between April 29, 2025 and August 5, 2025, both dates inclusive (the “Class Period”), have until Monday, October 20, 2025 to seek appointment as lead plaintiff of the Snap class action lawsuit. Captioned Abdul-Hameed v. Snap Inc., No. 25-cv-07844 (C.D. Cal.), the Snap class action lawsuit charges Snap and certain of Snap’s top executives w ...

NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Savara Inc. (NASDAQ: SVRA) between March 7, 2024 and May 23, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 7, 2025. SO WHAT: If you purchased Savara securities during the Class Period y ...